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SUPERIOR COURT
CIVIL ACTION
DOCKET NO. CV-19-

STATE OF MAINE
KENNEBEC, SS.

)
)
)
)
)
)

STATE OF MAINE,
Plaintiff
V.

.

CONSENT JUDGMENT

)
)
)
)
)

JOHNSON & JOHNSON
and ETHICON, INC.,
Defendants

Plaintiff, the State of Maine (“Plaintiff’), by and through its Attorney General Aaron M.
Frey, has filed a Complaint for a permanent injunction and other relief in this matter pursuant to 5
M.R.S.A. § 209 o f the Maine Unfair Trade Practices Act (the “MUTPA,” 5 M.R.S.A. §§ 205-A
through 214) alleging that Defendants Johnson & Johnson and Ethicon, Inc., a wholly-owned
subsidiary of Defendant Johnson & Johnson, committed violations of the aforementioned
Act. Plaintiff, by its counsel, and Defendants, by counsel, have agreed to the entry o f this Consent
Judgment (“Judgment”) by the Court without trial or adjudication o f any issue o f fact or law, and
without finding or admission o f wrongdoing or liability o f any kind.
IT IS HEREBY ORDERED THAT:
I.

FINDINGS

1.1

This Court has jurisdiction over the subject matter o f this lawsuit and over all

1.2

The terms o f this Judgment shall be governed by the laws o f the State o f Maine.

1.3

Entry o f this Judgment is in the public interest and reflects a negotiated agreement

Parties.

among the Parties.

1

i

1.4

The Parties have agreed to resolve the issues resulting from the Covered Conduct

by entering into this Judgment.1
1.5

Defendants are willing to enter into this Judgment regarding the Covered Conduct

in order to resolve the Attorneys General’s concerns under the State Consumer Protection Laws as
to the matters addressed in this Judgment and thereby avoid significant expense, inconvenience,
and uncertainty.
1.6

Defendants are entering into this Judgment solely for the purpose of settlement, and

nothing contained herein may be taken as or construed to be an admission or concession o f any
violation o f law, rule, or regulation, or o f any other matter o f fact or law, or of any liability or
wrongdoing, all o f which Defendants expressly deny. Defendants do not admit any violation of
the State Consumer Protection Laws set forth in footnote 4, and do not admit any wrongdoing that
was or could have been alleged by any Attorney General before the date o f the Judgment under
those laws. No part o f this Judgment, including its statements and commitments, shall constitute
evidence o f any liability, fault, or wrongdoing by Defendants. This document and its contents are
not intended for use by any third party for any purpose, including submission to any court for any
purpose.
1.7

This Judgment shall not be construed or used as a waiver or limitation o f any

defense otherwise available to Defendants in any other action, or o f Defendants’ right to defend
from, or make any arguments in, any private individual action, class claims or suits, or any other
governmental or regulatory action relating to the subject matter or terms o f this Judgment. This
Judgment is made without trial or adjudication o f any issue o f fact or law or finding o f liability o f
any kind. Notwithstanding the foregoing, a State may file an action to enforce the terms o f this
Judgment.

i This Judgment is entered into pursuant to and subject to the State Consumer Protection Laws cited in footnote 4.
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1.8

It is the intent of the Parties that this Judgment not be admissible in other cases or

binding on Defendants in any respect other than in connection with the enforcement o f this
Judgment.
1.9

N o part o f this Judgment shall create a private cause of action or confer any right

to any third party for violation of any federal or state statute.
1.10

This Judgment (or any portion thereof) shall in no way be construed to prohibit

Defendants from making representations with respect to any Ethicon products that are required
under Federal law or regulations or in Food and Drug Administration (“FDA”) approved or cleared
Labeling.
1.11

Nothing in this Judgment shall require Defendants to:

(a) .

Take any action that is prohibited by the Food, Drug and Cosmetic Act, 21 U.S.C.
§ 301 et seq. (“FDCA”) or any regulation promulgated thereunder, or by the
FDA; or

(b) .

Fail to take any action that is required by the FDCA or any regulation promulgated
thereunder, or by the FDA.
H.

DEFINITIONS

The following definitions shall be used in construing the Judgment:
2.1

“Covered Conduct” shall mean Ethicon’s marketing and promotional practices, and

dissemination o f information to Health Care Providers (“HCPs”) and consumers, regarding
Surgical M esh products up to the Effective Date of the Judgment.
2.2

“Effective Date” shall mean the date on which a copy o f the Judgment, duly

executed by Defendants and by the Signatory Attorney General, is approved by, and becomes a
Judgment o f the Court.
2.3

“Health Care Provider” or “HCP” shall mean any physician or other health care
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practitioner who is licensed to provide health care services or to prescribe pharmaceutical products
and/or medical devices.
2.4

“Defendants” shall mean Johnson & Johnson, Ethicon, Inc., and all o f their officers,

directors, employees, representatives, agents, affiliates, parents, subsidiaries, assigns and
successors.
2.5

“Multistate Executive Committee” shall mean the Attorneys General and their

staffs representing Florida, Indiana, Maryland, Ohio, South Carolina, and Texas.
2.6

“Multistate Working Group” shall mean the Attorneys General and their staffs

representing Alabama, Alaska, Arizona, Arkansas, Colorado, Connecticut, Delaware, District of
Columbia, Delaware, Florida, Georgia, Hawaii2, Idaho, Illinois, Indiana, Iowa, Kansas, Louisiana,
Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nebraska, Nevada, New Jersey,
New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, Rhode
Island, South Carolina, South Dakota, Tennessee, Texas, Utah3, Vermont, Virginia, and
Wisconsin.
2.7

“Parties” shall mean Defendants as defined in Subsection 2.4 and the Signatory

Attorney General.
2.8

“Promotion,” “Promotional,” “Promoting,” “Promote,” or “Promoted” shall mean

any representation made to HCPs, patients, consumers, payors or other customers, and other
practices intended to increase sales or that attempt to influence prescribing practices o f HCPs.

2 Hawaii is being represented on this matter by its Office o f Consumer Protection, an agency which is not part o f the
state Attorney General’s Office, but which is statutorily authorized to undertake consumer protection functions,
including legal representation o f the State o f Hawaii. For simplicity, the entire group will be referred to as the
“Attorneys General,” and such designation, as it includes Hawaii, refers to the Executive Director of the State o f
Hawaii Office o f Consumer Protection.
3 With regard to Utah, the Utah Division o f Consumer Protection is charged with administering and enforcing the
Consumer Sales Practices Act, the statute relevant to this Judgment. References to the "States," "Parties," or
"Attorneys General," with respect to Utah, refers to the Utah Division o f Consumer Protection.
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2.9

“Risks” shall mean the complications of Surgical Mesh, including complications

discovered subsequent to the Effective Date, which constitute clinically significant risks material
to an HCP’s decision to implant Surgical Mesh. Risks shall be set forth in the Surgical Mesh
Instructions-for-Use/Information-for-Use (“IFU/IFUs”), and include the following:
■ Complications that cannot be eliminated with surgical technique;
■ Complications that are specifically associated with the use o f Surgical Mesh (as
opposed to non-mesh surgery); and
■ Complications that are otherwise specified in this Judgment.
2.10

“Signatory Attorney General” shall mean the Attorney General o f Maine, or his

authorized designee, who has agreed to this Judgment.
2.11

“Sponsor,” “Sponsorship,” or “Sponsored” shall mean to pay for in whole or in

part, to provide financial support or subsidization, or to provide goods or materials o f value in
support, but does not include de minimis contributions of money, goods, or materials.
2.12

“State Consumer Protection Laws” shall mean the consumer protection laws cited

in footnote 4 under which the Attorneys General have conducted the investigation.45

4ALABAMA —Alabama Deceptive Trade Practices Act § 8-19-1 et seq. (2002); ALASKA —Alaska Unfair Trade
Practices and Consumer Protection Act AS 45.50.471 - 45.50.561; ARIZONA - Consumer Fraud Act, A.R.S. §441521 et seq.; ARKANSAS - Arkansas Deceptive Trade Practices Act, Ark. Code Ann. § 4-88-101, et seq.;
COLORADO — Colorado Consumer Protection Act, Colo. Rev. Stat. § 6-1-101 et seq.; CONNECTICUT Connecticut Unfair Trade Practices Act, Conn. Gen Stat. §§ 42-110a through 42-1 lOq; DELAWARE —Delaware
Consumer Fraud Act, Del. CODE ANN. tit. 6, §§ 2511 to 2527; DISTRICT OF COLUMBIA, District o f Columbia
Consumer Protection Procedures Act, D.C. Code §§ 28-3901 et seq.; FLORIDA-Florida Deceptive and Unfair Trade
Practices Act, Part II, Chapter 501, Florida Statutes, 501.201 et. seq.; GEORGIA - Fair Business Practices Act,
O.C.G.A. Sections 10-1-390 et seq.; HAWAII - Uniform Deceptive Trade Practice Act, Haw. Rev. Stat. Chpt. 481A
and Monopolies; Restraint o f Trade, Haw. Rev. Stat. Chpt. 480; IDAHO - Idaho Consumer Protection Act, Idaho
Code § 48-601 et seq.; ILLINOIS - Consumer Fraud and Deceptive Business Practices Act, 815 ILCS 510/1 et seq.
and Illinois Uniform Deceptive Trade Practices Act, 815 ILCS 510/1 et seq.; INDIANA - Deceptive Consumer Sales
Act, Ind. Code §§ 24-5-0.5-0.1 to 24-5-0.5-12; IOWA - Iowa Consumer Fraud Act, Iowa Code Section 714.16;
KANSAS - Kansas Consumer Protection Act, K.S.A. 50-623 et seq.; LOUISIANA - Unfair Trade-Practices and
Consumer Protection Law, LSA-R.S. 51:1401, et seq.; MAINE - Maine Unfair Trade Practices Act, 5 M.R.S.A. §§
205-A through 214; MARYLAND - Maryland Consumer Protection Act, Md. Code Ann., Com. Law §§ 13-101 et
seq.; M ASSACHUSETTS-M ass. Gen. Laws c. 93A, §§ 2 and 4; MICHIGAN - Michigan Consumer Protection Act,
MCL § 445.901 et seq.; MISSOURI - Missouri Merchandising Practices Act, Mo. Rev. Stat. §§ 407.010 et seq.;
MONTANA - Montana Consumer Protection Act §§ 30-14-101 et seq.; NEBRASKA - Consumer Protection Act,
Neb. Rev. Stat. §§ 59-1601 et seq. and Uniform Deceptive Trade Practices Act, Neb. Rev. Stat. §§ 87-301 et seq.;
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2.13

“Surgical Mesh” shall mean any medical device (as the term “device” is defined in

21 U.S.C. § 321(h)) that contains synthetic, multi-strand, knitted or woven mesh and that is
intended for transvaginal implantation in the pelvic floor to treat stress urinary incontinence
(“SUI”) and/or pelvic organ prolapse (“POP”).
2.14

“Valid Scientific Evidence” shall have the meaning set forth in 21 CFR § 860.7.

2.15

Any reference to a written document shall mean a physical paper copy o f the

document, electronic version o f the document, or electronic access to such document.
ffl.
A.

COMPLIANCE PROVISIONS

General Provision
3.1

Ethicon shall not violate 5 M.R.S.A. § 207 o f the MUTPA in Promoting Surgical

Mesh or in any material accompanying its Surgical Mesh.
B.

Device Labeling: Warnings and Precautions, Adverse Reactions and Other Adverse
Reactions
The following subsections o f Section III shall be effective for five (5) years from the

Effective Date o f this Judgment.
3.2

As soon as practicable, but no later than 24 months from the Effective Date o f this

Judgment, Ethicon shall, in addition to disclosing the relevant hazards, contraindications, side

NEVADA - Deceptive Trade Practices Act, Nevada Revised Statutes 598.0903 et seq.; NEW JERSEY - New Jersey
Consumer Fraud Act, NJSA 56:8-1 et seq.; NEW MEXICO - NMSA 1978, § 57-12-1 to -26 (1967, as amended
through 2019); NEW YORK - General Business Law Art. 22-A, §§ 349-50, and Executive Law § 63(12); NORTH
CAROLINA -N orth Carolina Unfair and Deceptive Trade Practices Act, N.C.G.S. 75-1.1, et seq.; NORTH DAKOTA
- Unlawful Sales or Advertising Practices, N.D. Cent. Code § 51-15-02 et seq.; OHIO — Ohio Consumer Sales
Practices Act, R.C. 1345.01, et seq.; OKLAHOMA - Oklahoma Consumer Protection Act 15 O.S. §§ 751 et seq.;
PENNSYLVANIA - Pennsylvania Unfair Trade Practices and Consumer Protection Law, 73 P.S. § 201-1 et seq.;
RHODE ISL A N D -D eceptive Trade Practices Act, Rhode Island Gen. Laws § 6-13.1-1, etseq.; SOUTH CAROLINA
—South Carolina Unfair Trade Practices Act, S.C. Code Ann. § 39-5-10 et seq.; SOUTH DAKOTA - South Dakota
Deceptive Trade Practices and Consumer Protection, SDCL ch, 37-24; TENNESSEE - Tennessee Consumer
Protection Act, Term. Code Ann. 47-18-101 et seq.; TEXAS - Texas Deceptive Trade Practices-Consumer Protection
Act, Tex. Bus. And Com. Code 17.41, et seq.; UTAH - Consumer Sales Practices Act, Utah Code Ann. §§ 13-11-1 et
seq.; VERMONT - Vermont Consumer Protection Act, 9 V.S.A. § 2451, et seq.; VIRGINIA-Virginia Consumer
Protection Act, Va Code Ann. §59.1-196 et seq.; W ISC O N SIN -W is. Stat. § 100.18 (Fraudulent Representations).
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effects, and precautions that are set forth in its IFUs as o f July 30, 2018, ensure that the IFUs for
its Surgical Mesh devices:
(a) .

Do not represent that the Surgical M esh provides in vivo elasticity, including in vivo

elasticity in both directions.
(b) .

Do not represent that the Surgical Mesh will remain soft, supple, or pliable after

implantation.
(c) .

Do not represent that any inflammatory or foreign body reaction is only transient

or, in all instances, minimal.
(d) .

Do not represent that a foreign body reaction “may occur” with implantation o f the

device, but instead indicate that a foreign body reaction to the device will occur, the extent of
which may differ and may result in adverse reactions, which may be ongoing.
(e) .

State that Risks include fistula formation, inflammation, and ongoing risks o f mesh

extrusion, exposure, and erosion into the vagina and other structures or organs.
(f)

.

State that Risks include temporary or permanent voiding dysfunction or obstructive

voiding in addition to, and independent from, temporary or permanent lower urinary tract
obstruction caused by overcorrection.
(g)

State that Risks include excessive contraction or shrinkage o f the tissue surrounding

the mesh.
(h) .

State that Risks include pain with intercourse and loss o f sexual function, which in

some patients may not resolve.
(i) .

State that Risks include that one or more revision surgeries may be necessary to

treat complications that result from the implantation o f a Surgical Mesh device, that revision
surgeries may not resolve the complications, and that revision surgeries are also associated with a
risk of adverse reactions.

7

(j) .

State that Risks include urge incontinence, including de novo urge incontinence.

(k) . State that Risks include a risk of infection following transvaginal implantation.
(l) . State that Risks include the risk of vaginal scarring from causes which include, but
are not limited to, mesh exposure.
3.3

Risk information contained in any o f Ethicon’s Surgical Mesh IFUs shall only be

removed if such a change is supported by Valid Scientific Evidence or undertaken at the behest of
the FDA.
3.4

Ethicon shall evaluate emerging Risk information for Surgical Mesh, and as soon

as practicable, modify Ethicon’s Surgical Mesh IFUs to include any such emerging Risk
information and communicate any modification o f the Risk information in the Surgical Mesh IFUs
to HCPs accordingly, and to the individuals responsible for Ethicon Marketing so as to modify any
Promotional communication for Surgical Mesh in accordance with any modified Risk information.
3.5

Ethicon shall ensure that the language within each of its Surgical M esh IFUs is

internally consistent and that the language addressing Risks within a Surgical M esh IFU is in no
way contradicted by, or in any way conflicts with, other language within the IFU.
C.

Promotion
3.6

Ethicon shall not make any representations in its Promotion for Surgical Mesh that

contradict or are inconsistent with information, including Risk information, contained in the
Surgical Mesh IFU or IFUs for the product or products addressed in the Promotion, including as
such IFUs are amended pursuant to this Judgment, nor make any representations in its Promotion
regarding Surgical Mesh that Ethicon has removed from any of its IFUs pursuant to this Judgment.
3.7

Ethicon shall not, in any Promotion for Surgical Mesh, represent or imply that Risks

associated with Surgical Mesh can be eliminated with surgical experience or technique alone
unless such claim is supported by Valid Scientific Evidence.
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3.8

Ethicon shall not, in any Promotion for Surgical Mesh, misrepresent the extent to

which Risks associated with Surgical Mesh are common to pelvic floor or other surgeries.
3.9

Ethicon shall not make any claim comparing the safety or efficacy o f the use of

Surgical Mesh to any non-mesh procedure unless the claim is supported by Valid Scientific
Evidence.
3.10

Ethicon shall not represent in any Promotion for Surgical Mesh that Surgical Mesh

is “FDA approved” or that it has undergone the FDA’s Premarket Approval (“PM A”) process,
including any requirement for clinical trials, unless such is the case. Ethicon shall train each sales
representative who promotes or sells any of Ethicon’s Surgical Mesh products on the accurate
FDA approval or clearance status o f each Surgical Mesh product that the sales representative
promotes or sells in advance of any such promotion or sale.
3.11

Ethicon shall not, in any Promotion for Surgical Mesh, misrepresent FDA update(s)

or communication(s) regarding Surgical Mesh.
3.12

In any written or electronic Promotion that is intended to reach patients, consumers,

or Health Care Providers, Ethicon shall include a complete description of Risks set forth in the
respective IFU for the Surgical Mesh Product, but in written or electronic Promotion intended for
patients or other non-Health Care Providers, in language that is understandable for the consumer
or patient.
3.13

In any Promotion that is intended to reach HCPs that addresses any particular aspect

of Surgical Mesh which is specifically addressed in the IFU for that Surgical M esh device, Ethicon
shall provide a complete description of the Risks set forth in the respective LFU for the Surgical
Mesh Product which the Promotion addresses.
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D.

(

Health Care Provider Training
3.14

In any training that Ethicon Sponsors and/or undertakes to provide to any HCP

regarding its Surgical Mesh, Ethicon shall ensure that such training informs the HCP about all
Risks included in the applicable IFU. In addition, such training must otherwise comply with the
requirements o f Subsection C, above.
E.

Sponsorship
3.15

By the following means, Ethicon shall ensure that its Sponsorship o f any

professional event, training material, clinical program, research, grant, or publication concerning
Surgical Mesh is disclosed:
(a) .

When submitting a clinical study, clinical data, or pre-clinical data regarding

Surgical Mesh for publication, Ethicon shall adhere to the most recent Recommendations for the
Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals developed
by the International Committee o f Medical Journal Editors (“ICMJE”) guidelines for the naming
of authors.
(b) .

In all contracts for consulting services regarding Surgical Mesh between Ethicon

and any HCP or other author/consultant (hereinafter “HCP Contract”), Ethicon shall include a
sponsorship disclosure provision under which the HCP or other author/consultant agrees that he
or she shall, in terms and in a manner so as to be clearly noticed and understood by the audience,
disclose in any public presentation or submission for publication Ethicon’s Sponsorship o f the
contracted-for activities (including all Sponsorship information required by any publication’s
conflict disclosure requirements). Ethicon shall also include a disclosure clause in any HCP
Contract under which the HCP or other author/consultant acknowledges that Ethicon may publicly
report Ethicon’s value transfers to him or her.
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3.16

In all Ethicon-sponsored manuscripts, publications, or presentations reporting the

results o f an Ethicon-sponsored study, Ethicon shall disclose Ethicon’s role as a Sponsor, and any
author’s potential conflict o f interest, consistent with the conflict o f interest disclosure
requirements of the ICMJE.
F.

Clinical Research
3.17

Ethicon shall, when citing to any clinical study, clinical data, or preclinical data in

any Promotion, present a fair balance of that clinical study, clinical data, or preclinical data and
disclose any role as a Sponsor.
3.18

Ethicon shall not use any Promotion that references clinical or preclinical data

relating to any o f its Surgical Mesh devices over which it has had possession, custody, or control
unless Ethicon has retained possession, custody, or control over such clinical data or preclinical
data.
G.

Monitoring and Compliance
3.19

Ethicon shall be responsible for ensuring monitoring and compliance with the

provisions o f this Judgment.
IV. PAYMENT
4.1

No later than 30 days after the Effective Date of this Judgment, Defendants shall

pay a total amount o f One Hundred Sixteen Million Eight Hundred and Sixty Thousand Dollars
($116,860,000.00) to be divided and paid collectively by Defendants to each Signatory Attorney
General o f the Multistate Working Group in an amount to be designated by and in the sole
discretion o f the Multistate Executive Committee.5 Said payment shall be used by the States as
attorneys’ fees and other costs o f investigation and litigation, or to be placed in, or applied to,

5 The payment to the Signatory Attorney General under this Section shall be $1,515,946.44.
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consumer protection enforcement, including future consumer protection enforcement, consumer
education, litigation or local consumer aid fund or revolving fund, used to defray the costs o f the
inquiry leading hereto, or for any lawful purpose, at the sole discretion of each Signatory Attorney
General. The Parties acknowledge that the payment described herein is not a fine, penalty, or
payment in lieu thereof.
V. ENFORCEMENT
5.1

For the purposes o f resolving disputes with respect to compliance with this

Judgment, should any o f the Signatory Attorneys General have a reasonable basis to believe that
Ethicon has engaged in a practice that violates a provision o f this Judgment subsequent to the
Effective Date, then such Attorney General shall notify Ethicon in writing o f the specific objection,
identify with particularity the provision o f this Judgment that the practice appears to violate, and
give Ethicon thirty (30) days to respond to the notification; provided, however, that a Signatory
Attorney General may take any action if the Signatory Attorney General believes that, because o f
the specific practice, a threat to the health or safety o f the public requires immediate action. Upon
receipt o f written notice, Ethicon shall provide a good-faith written response to the Attorney
General notification, containing either a statement explaining why Ethicon believes it is in
compliance with the Judgment, or a detailed explanation o f how the alleged violation occurred and
a statement explaining how Ethicon intends to remedy the alleged breach. Nothing in this Section
shall be interpreted to limit the State o f Maine’s Civil Investigative Demand (“CID”) or
investigative subpoena authority, to the extent such authority exists under applicable law, and
Defendants reserve all o f their rights in responding to a CID or investigative subpoena issued
pursuant to such authority.
5.2

Upon giving Ethicon thirty (3 0) days to respond to the notification described above,

the Signatory Attorney General shall also be permitted reasonable access to inspect and copy
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relevant, non-privileged, non-work product records and documents in the possession, custody, or
control o f Ethicon that relate to Ethicon’s compliance with each provision o f this Judgment
pursuant to that State’s CID or investigative subpoena authority. If the Signatory Attorney General
makes or requests copies o f any documents during the course o f that inspection, the Signatory
Attorney General will provide a list o f those documents to Ethicon.
5.3

The State may assert any claim that Ethicon has violated this Judgment in a separate

civil action to enforce compliance with this Judgment, or may seek any other relief afforded by
law for violations o f the Judgment, but only after providing Ethicon an opportunity to respond to
the notification described in Subsection 5.1 above; provided, however, that a Signatory Attorney
General may take any action if the Signatory Attorney General believes that, because o f the
specific practice, a threat to the health or safety o f the public requires immediate action.
VI.
6.1

RELEASE

Released Claims. By its execution o f this Judgment, the State o f Maine releases

and forever discharges Defendants and their past and present officers, directors, employees,
representatives, agents, affiliates, parents, subsidiaries, predecessors, assigns and successors
(collectively, the “Releasees”) from the following: all civil causes o f action, claims, damages,
costs, attorney’s fees, or penalties that the Maine Attorney General has asserted or could have
asserted against the Releasees under the State Consumer Protection Laws resulting from the
Covered Conduct up to and including the Effective Date.
6.2

Claims Not Covered. Notwithstanding any term o f this Judgment, specifically

reserved and excluded from the release in Subsection 6.1 as to any entity or person, including
Releasees, are any and all o f the following:
(a).

Any criminal liability that any person or entity, including Releasees, has or may

have to the State o f Maine;
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(b) .

Any civil or administrative liability that any person and/or entity, including

Releasees, has or may have to the State o f Maine not expressly covered by the release in
Subsection 6.1, including, but not limited to, any and all o f the following claims:
i.

State or federal antitrust violations;

ii

Claims involving “best price,” “average wholesale price,” “wholesale
acquisition cost,” or any reporting practices;

iii.

Medicaid claims including, but not limited to, Medicaid fraud or abuse
(whether common law, statutory or otherwise), and/or kickback violations
related to any state’s Medicaid program;

(c) .

iv.

State false claims violations; and

v.

Claims to enforce the terms and conditions o f this Judgment.

Actions of, or on behalf of, state program payors o f the State o f Maine arising

from the purchase o f Surgical Mesh.
(d) .

Any claims individual consumers have or may have under above-cited State

Consumer Protection Laws against any person or entity, including the Releasees.
6.3

Nothing contained in this Judgment shall relieve Defendants o f the obligations

they maintain under any other Judgment or agreement relating to any product.
VII.
7.1

ADDITIONAL PROVISIONS

Nothing in this Judgment shall be construed to authorize or require any action by

Defendants in violation of applicable federal, state, or other laws.
7.2

Modification. The Judgment may be modified by a stipulation o f the Parties, once

the stipulation is approved by and becomes a judgment o f the Court, or by court proceedings
resulting in a modified judgment o f the Court.
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7.3

1

The Defendants shall not cause or encourage third parties, nor knowingly permit

third parties acting on the behalf o f either Defendant, to engage in practices from which either
Defendant is prohibited by this Judgment.
7.4

The acceptance o f this Judgment by the State o f Maine shall not be deemed

approval by the State o f Maine o f any o f Defendants’ past, present, or future advertising or business
practices. Further, neither Defendants nor anyone acting on their behalf shall state or imply, or
cause to be stated or implied, that the State o f Maine or any other governmental unit o f the State
o f Maine has approved, sanctioned or authorized any past, present, or future practice, act,
advertisement, or conduct of either Defendant.
7.5

Any failure by any party to this Judgment to insist upon the strict performance by

any other party of any o f the provisions o f this Judgment shall not be deemed a waiver o f any o f
the provisions of this Judgment, and such party, notwithstanding such failure, shall have the right
thereafter to insist upon the specific performance o f any and all o f the provisions o f this Judgment.
7.6

Entire Agreement. This Judgment represents the full and complete terms o f the

settlement entered into by the Parties hereto. In any action undertaken by the Parties, no prior
versions o f this Judgment and no prior versions o f any o f its terms that were not entered by the
Court in this Judgment, may be introduced for any purpose whatsoever.
7.7

Jurisdiction. This Court retains jurisdiction o f this Judgment and the Parties hereto

for the purpose o f enforcing and modifying this Judgment and for the purpose of granting such
additional relief as may be necessary and appropriate.
7.8

Counterparts. This Judgment may be executed in counterparts, and a facsimile or

.pdf signature shall be deemed to be, and shall have the same force and effect as, an original
signature.

15

7.9

Notice. All Notices under this Judgment shall be provided to the following via

email and Overnight Mail:
Defendants:
William Craco and Shelly Goldklang
Johnson & Johnson Law Department
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
wcraco@its.jnj .com
sgoldkla@its.jnj .com
Copy to Defendants’ attorneys at
O’Melveny & Myers LLP and Covington & Burling LLP
via electronic mail sent to:
Steve Brody (sbrody@omm.com)
Carolyn Kubota (ckubota@cov.com)
Signatory Attorney General:
Linda J. Conti
Chief, Consumer Protection Division
Office o f the Maine Attorney General
Burton Cross Office Building, 6th Floor
111 Sewall Street
Augusta, M E 04330
linda. conti@maine. go v
7.10

To the extent that any provision o f this Judgment obligates Defendants to change

any policy(ies) or procedure(s) and to the extent not already accomplished, Defendants shall
implement the policy(ies) or procedure(s) as soon as reasonably practicable, but no later than 120
days after the Effective Date o f this Judgment, unless another period for compliance is specified
herein.
IT IS SO ORDERED, ADJUDGED AND DECREED.

Dated:

, * \ > \ 1M

16

Plaintiff State of Maine:
Aaron M. Frey
Attorney General

Date:
Assistant Attorney General
\S
Office o f the Maine Attorney General
6 State House Station
Augusta, ME 04333-0006
(207) 626-8800
Carolyn. silsby@maine. gov
Counsel for Plaintiff
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(
Defendant Johnson & Johnson:

Date:

tt> 111 n ?

ßy:

QmaI

Renee Brutus
Assistant Corporate Secretary

Defendant Ethicon, Inc.

D ate:

tòj/ulì

Approved as to form:

Date:

By: ____________________
Stephen D. Brody
O ’Melveny & Myers
1625 Eye Street, NW
Washington, DC 20006
202-383-5300
sbrodv@omm.com
Counsel for Defendants

Date:

By: ____________________________________
James M. Campbell ME Bar ID: 3551
Campbell Conroy & O ’Neil, P.C.
1 Constitution Wharf, Suite 310
Boston, MA 02129
P: 617-241-3000
F: 617-241-5115
imcampbell@campbell-trial-lawyers.com

Local Counsel for Defendants
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Defendant Johnson & Johnson:

Date:

By: _____
Name
Title

Defendant Ethicon, Inc.

Date:

By: _____
Name
Title

Approved as to form:
Date:

Counsel for Defendants

Date:
3551
s M. Campbel
fampbell Conroy & O ’Neil, P.C.
1 Constitution Wharf, Suite 310
Boston, MA 02129
P: 617-241-3000
F: 617-241-5115
imcampbell@campbell-trial-lawvers.com
Local Counsel for Defendants
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Defendant Johnson & Johnson:

Date:

By: _________________________
Tina French
Assistant Corporate Secretary

Defendant Ethicon, Inc.

Date:

By:
Tina French
Assistant Corporate Secretary

Approved as to form:

202-383-5300
sbrodv@omm.com
Counsel for Defendants

Date:

By: ___________________________________
James M. Campbell ME Bar ID: 3551
Campbell Conroy & O’Neil, P.C.
1 Constitution Wharf, Suite 310
Boston, MA 02129
P: 617-241-3000
F: 617-241-5115
7mcampbeil@camDbeil-trial-iawyers.com

Local Counsel for Defendants
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